Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Epigenetic Suppression of the T-box Subfamily 2 (TBX2) in Human Non-Small Cell Lung Cancer.

Nehme E, Rahal Z, Sinjab A, Khalil A, Chami H, Nemer G, Kadara H.

Int J Mol Sci. 2019 Mar 7;20(5). pii: E1159. doi: 10.3390/ijms20051159.

2.

Decreased expression of connective tissue growth factor in non-small cell lung cancer is associated with clinicopathological variables and can be restored by epigenetic modifiers.

Drzewiecka H, Gałęcki B, Jarmołowska-Jurczyszyn D, Kluk A, Dyszkiewicz W, Jagodziński PP.

J Cancer Res Clin Oncol. 2016 Sep;142(9):1927-46. doi: 10.1007/s00432-016-2195-3. Epub 2016 Jul 8.

3.

TBX2 subfamily suppression in lung cancer pathogenesis: a high-potential marker for early detection.

Khalil AA, Sivakumar S, Lucas FAS, McDowell T, Lang W, Tabata K, Fujimoto J, Yatabe Y, Spira A, Scheet P, Nemer G, Kadara H.

Oncotarget. 2017 Aug 4;8(40):68230-68241. doi: 10.18632/oncotarget.19938. eCollection 2017 Sep 15.

4.

[Effects of 5-Aza-2-deoxycytidine on DNA methylation of anti-oncogenes in non-small cell lung cancer cells].

Fang HL, Yu ZC, Zhu HB, Jin YT.

Zhonghua Zhong Liu Za Zhi. 2012 Sep;34(9):658-63. doi: 10.3760/cma.j.issn.0253-3766.2012.09.004. Chinese.

PMID:
23159077
5.

Methylated +322-327 CpG site decreases hOGG1 mRNA expression in non-small cell lung cancer.

Zeng Y, Zhu J, Qin H, Shen D, Lei Z, Li W, Ding Z, Huang JA, Liu Z.

Oncol Rep. 2017 Jul;38(1):529-537. doi: 10.3892/or.2017.5690. Epub 2017 Jun 1.

PMID:
28586012
6.

Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.

Miao Y, Wang L, Zhang X, Xu X, Jiang G, Fan C, Liu Y, Lin X, Yu J, Zhang Y, Wang E.

PLoS One. 2014 Nov 14;9(11):e112258. doi: 10.1371/journal.pone.0112258. eCollection 2014.

7.

Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.

Tang X, Yin X, Xiang T, Li H, Li F, Chen L, Ren G.

Cancer Biomark. 2012-2013;12(1):11-9. doi: 10.3233/CBM-2012-00280.

PMID:
23321465
8.
9.

Increased expression of 17-beta-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer.

Drzewiecka H, Gałęcki B, Jarmołowska-Jurczyszyn D, Kluk A, Dyszkiewicz W, Jagodziński PP.

Lung Cancer. 2015 Feb;87(2):107-16. doi: 10.1016/j.lungcan.2014.12.012. Epub 2014 Dec 25.

PMID:
25564397
10.

Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers.

Imoto I, Izumi H, Yokoi S, Hosoda H, Shibata T, Hosoda F, Ohki M, Hirohashi S, Inazawa J.

Cancer Res. 2006 May 1;66(9):4617-26.

11.

SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers.

Altenberger C, Heller G, Ziegler B, Tomasich E, Marhold M, Topakian T, Müllauer L, Heffeter P, Lang G, End-Pfützenreuter A, Döme B, Arns BM, Klepetko W, Zielinski CC, Zöchbauer-Müller S.

Mol Cancer. 2017 Jan 5;16(1):1. doi: 10.1186/s12943-016-0568-5.

12.

Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas.

Heller G, Fong KM, Girard L, Seidl S, End-Pfützenreuter A, Lang G, Gazdar AF, Minna JD, Zielinski CC, Zöchbauer-Müller S.

Oncogene. 2006 Feb 9;25(6):959-68.

PMID:
16205641
13.

LHX6 acts as a novel potential tumour suppressor with epigenetic inactivation in lung cancer.

Liu WB, Jiang X, Han F, Li YH, Chen HQ, Liu Y, Cao J, Liu JY.

Cell Death Dis. 2013 Oct 24;4:e882. doi: 10.1038/cddis.2013.366.

14.

Transcriptomic Alterations in Lung Adenocarcinoma Unveil New Mechanisms Targeted by the TBX2 Subfamily of Tumor Suppressor Genes.

Khalil A, Dekmak B, Boulos F, Kantrowitz J, Spira A, Fujimoto J, Kadara H, El-Hachem N, Nemer G.

Front Oncol. 2018 Oct 30;8:482. doi: 10.3389/fonc.2018.00482. eCollection 2018.

15.

Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.

Yue W, Dacic S, Sun Q, Landreneau R, Guo M, Zhou W, Siegfried JM, Yu J, Zhang L.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4336-44.

16.

Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.

Kaira K, Sunaga N, Tomizawa Y, Yanagitani N, Ishizuka T, Saito R, Nakajima T, Mori M.

Int J Oncol. 2007 Jul;31(1):169-73.

PMID:
17549418
17.

Epigenetic mechanisms for silencing glutathione S-transferase m2 expression by hypermethylated specificity protein 1 binding in lung cancer.

Tang SC, Wu MF, Wong RH, Liu YF, Tang LC, Lai CH, Hsu CP, Ko JL.

Cancer. 2011 Jul 15;117(14):3209-21. doi: 10.1002/cncr.25875. Epub 2011 Jan 18.

18.

Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.

Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, Khuri FR.

Clin Cancer Res. 2002 May;8(5):1178-84.

19.

Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.

Zhang Y, Miao Y, Yi J, Wang R, Chen L.

Clin Lung Cancer. 2010 Jul 1;11(4):264-70. doi: 10.3816/CLC.2010.n.034.

PMID:
20630829
20.

Supplemental Content

Support Center